Parnax Lab (PARNAXLAB) | Financial Analysis & Statements
Parnax Lab Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
533.8M
Gross Profit
233.9M
43.83%
Operating Income
54.9M
10.29%
Net Income
32.7M
6.14%
EPS (Diluted)
₹2.85
Balance Sheet Metrics
Total Assets
2.1B
Total Liabilities
1.2B
Shareholders Equity
901.4M
Debt to Equity
1.31
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Parnax Lab Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.9B | 1.9B | 1.7B | 1.6B | 900.6M |
| Cost of Goods Sold | 1.3B | 1.3B | 1.2B | 1.2B | 605.1M |
| Gross Profit | 627.2M | 554.3M | 512.7M | 480.2M | 295.5M |
| Gross Margin % | 33.4% | 29.4% | 30.6% | 29.5% | 32.8% |
| Operating Expenses | |||||
| Research & Development | 17.5M | 5.8M | 2.1M | 2.8M | 448.4K |
| Selling, General & Administrative | 90.8M | 70.9M | 69.6M | 63.8M | 48.2M |
| Other Operating Expenses | -1.0M | 386.3M | 67.0K | 1.2M | 1.2M |
| Total Operating Expenses | 107.3M | 463.1M | 71.7M | 67.8M | 49.8M |
| Operating Income | 197.9M | 166.7M | 167.5M | 172.1M | 49.9M |
| Operating Margin % | 10.5% | 8.8% | 10.0% | 10.6% | 5.5% |
| Non-Operating Items | |||||
| Interest Income | 1.9M | 4.2M | 2.3M | 1.6M | 862.4K |
| Interest Expense | 52.4M | 52.6M | 49.0M | 51.7M | 49.8M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 156.7M | 120.5M | 122.8M | 122.6M | -837.5K |
| Income Tax | 41.4M | 24.2M | 36.5M | 40.1M | 2.8M |
| Effective Tax Rate % | 26.4% | 20.1% | 29.7% | 32.7% | 0.0% |
| Net Income | 115.4M | 96.2M | 86.3M | 82.6M | -3.6M |
| Net Margin % | 6.1% | 5.1% | 5.2% | 5.1% | -0.4% |
| Key Metrics | |||||
| EBITDA | 285.4M | 242.0M | 239.9M | 233.4M | 101.3M |
| EPS (Basic) | ₹10.03 | ₹8.37 | ₹7.79 | ₹9.68 | ₹-0.43 |
| EPS (Diluted) | ₹10.03 | ₹8.37 | ₹7.79 | ₹9.68 | ₹-0.43 |
| Basic Shares Outstanding | 11485616 | 11485616 | 11069073 | 8512044 | 8504866 |
| Diluted Shares Outstanding | 11485616 | 11485616 | 11069073 | 8512044 | 8504866 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Parnax Lab Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 5.5M | 4.6M | 12.8M | 43.6M | 1.8M |
| Short-term Investments | 21.3M | 14.2M | 15.0M | 14.2M | 10.8M |
| Accounts Receivable | 307.6M | 325.6M | 278.9M | 380.8M | 167.1M |
| Inventory | 257.7M | 299.3M | 216.9M | 199.3M | 107.9M |
| Other Current Assets | 51.5M | 63.4M | 43.5M | 60.5M | 32.8M |
| Total Current Assets | 683.4M | 754.3M | 610.6M | 747.7M | 392.4M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 292.7M | 265.8M | 249.4M | 234.9M | 207.1M |
| Goodwill | 8.0M | 7.9M | 2.3M | 915.5K | 1.4M |
| Intangible Assets | 8.0M | 7.9M | 2.3M | 915.5K | 1.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 28.8M | 2.0K | -1.0K | -10 | 20 |
| Total Non-Current Assets | 1.2B | 1.1B | 840.1M | 787.0M | 670.2M |
| Total Assets | 1.9B | 1.9B | 1.5B | 1.5B | 1.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 213.5M | 221.8M | 147.6M | 220.8M | 62.3M |
| Short-term Debt | 432.8M | 507.0M | 393.8M | 485.1M | 417.7M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 15.6M | 6.2M | 6.1M | 8.0M | 4.6M |
| Total Current Liabilities | 743.3M | 818.3M | 630.4M | 809.8M | 543.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 262.4M | 299.4M | 153.3M | 205.7M | 171.3M |
| Deferred Tax Liabilities | 53.7M | 46.9M | 39.3M | 31.7M | 18.7M |
| Other Non-Current Liabilities | -1.0K | -2.0K | -1.0K | -10 | - |
| Total Non-Current Liabilities | 322.4M | 352.4M | 197.7M | 242.1M | 192.6M |
| Total Liabilities | 1.1B | 1.2B | 828.1M | 1.1B | 736.4M |
| Equity | |||||
| Common Stock | 114.9M | 114.9M | 114.9M | 98.1M | 85.0M |
| Retained Earnings | 554.2M | 439.0M | 342.9M | 256.7M | 174.3M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 832.4M | 716.9M | 622.6M | 482.8M | 326.2M |
| Key Metrics | |||||
| Total Debt | 695.3M | 806.4M | 547.2M | 690.7M | 589.0M |
| Working Capital | -59.9M | -64.0M | -19.8M | -62.1M | -151.3M |
Balance Sheet Composition
Parnax Lab Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 156.7M | 120.5M | 122.8M | 122.6M | -837.5K |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | 88.6M | -128.2M | 78.7M | -301.5M | 16.3M |
| Operating Cash Flow | 297.4M | 41.6M | 252.1M | -126.9M | 66.2M |
| Investing Activities | |||||
| Capital Expenditures | -70.4M | -319.3M | -100.2M | -178.2M | -44.8M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -7.1M | - | -826.0K | -3.3M | -1.7M |
| Investment Sales | - | 822.0K | 639.0K | 0 | - |
| Investing Cash Flow | -77.5M | -319.3M | -100.4M | -181.6M | -46.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | 90.3M | - | 34.3M | 36.3M |
| Debt Repayment | -104.2M | - | -145.7M | - | -31.9M |
| Financing Cash Flow | -177.8M | 201.6M | -183.0M | 173.6M | 87.6M |
| Free Cash Flow | 137.2M | -165.4M | 96.3M | -77.1M | -2.3M |
| Net Change in Cash | 42.1M | -76.0M | -31.2M | -134.9M | 107.3M |
Cash Flow Trend
Parnax Lab Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
14.43
Price to Book
2.01
Price to Sales
0.79
PEG Ratio
0.12
Profitability Ratios
Profit Margin
5.49%
Operating Margin
7.77%
Return on Equity
13.84%
Return on Assets
6.07%
Financial Health
Current Ratio
0.91
Debt to Equity
76.46
Beta
0.01
Per Share Data
EPS (TTM)
₹10.90
Book Value per Share
₹78.10
Revenue per Share
₹198.45
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| PARNAXLAB | 1.8B | 14.43 | 2.01 | 13.84% | 5.49% | 76.46 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





